iShares U.S. Healthcare ETF News - August 1, 2026

J&J secures $2.58B option for Sail Biomedicines, targeting in-body cell therapy

Johnson & Johnson secured an option to acquire Sail Biomedicines for up to $2.58 billion. This investment targets Sail’s novel in vivo chimeric antigen...